Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 963

1.

Hippocampal [18F]flortaucipir BPND corrected for possible spill-in of the choroid plexus retains strong clinico-pathological relationships.

Wolters EE, Ossenkoppele R, Golla SS, Verfaillie SC, Timmers T, Visser D, Tuncel H, Coomans EM, Windhorst AD, Scheltens P, van der Flier WM, Boellaard R, van Berckel BN.

Neuroimage Clin. 2019 Dec 2;25:102113. doi: 10.1016/j.nicl.2019.102113. [Epub ahead of print]

PMID:
31835238
2.

PET and CSF amyloid-β status are differently predicted by patient features: information from discordant cases.

Reimand J, de Wilde A, Teunissen CE, Zwan M, Windhorst AD, Boellaard R, Barkhof F, van der Flier WM, Scheltens P, van Berckel BNM, Ossenkoppele R, Bouwman F.

Alzheimers Res Ther. 2019 Dec 7;11(1):100. doi: 10.1186/s13195-019-0561-5.

3.

Why Is Amyloid-β PET Requested After Performing Cerebrospinal Fluid Biomarkers?

Reimand J, Groot C, Teunissen CE, Windhorst AD, Boellaard R, Barkhof F, Nazarenko S, van der Flier WM, van Berckel BNM, Scheltens P, Ossenkoppele R, Bouwman F.

J Alzheimers Dis. 2019 Nov 25. doi: 10.3233/JAD-190836. [Epub ahead of print]

PMID:
31796674
4.

Serotonergic deficits in dementia with Lewy bodies with concomitant Alzheimer's disease pathology: An 123I-FP-CIT SPECT study.

van der Zande JJ, Joling M, Happach IG, Vriend C, Scheltens P, Booij J, Lemstra AW.

Neuroimage Clin. 2019 Nov 1;25:102062. doi: 10.1016/j.nicl.2019.102062. [Epub ahead of print]

5.

Comorbid amyloid-β pathology affects clinical and imaging features in VCD.

Leijenaar JF, Groot C, Sudre CH, Bergeron D, Leeuwis AE, Cardoso MJ, Carrasco FP, Laforce R Jr, Barkhof F, van der Flier WM, Scheltens P, Prins ND, Ossenkoppele R.

Alzheimers Dement. 2019 Nov 27. pii: S1552-5260(19)35350-6. doi: 10.1016/j.jalz.2019.08.190. [Epub ahead of print]

6.

In pursuit of a sensitive EEG functional connectivity outcome measure for clinical trials in Alzheimer's disease.

Briels CT, Stam CJ, Scheltens P, Bruins S, Lues I, Gouw AA.

Clin Neurophysiol. 2019 Nov 4;131(1):88-95. doi: 10.1016/j.clinph.2019.09.014. [Epub ahead of print]

PMID:
31759193
7.

Global Burden of Small Vessel Disease-Related Brain Changes on MRI Predicts Cognitive and Functional Decline.

Jokinen H, Koikkalainen J, Laakso HM, Melkas S, Nieminen T, Brander A, Korvenoja A, Rueckert D, Barkhof F, Scheltens P, Schmidt R, Fazekas F, Madureira S, Verdelho A, Wallin A, Wahlund LO, Waldemar G, Chabriat H, Hennerici M, O'Brien J, Inzitari D, Lötjönen J, Pantoni L, Erkinjuntti T.

Stroke. 2019 Nov 8:STROKEAHA119026170. doi: 10.1161/STROKEAHA.119.026170. [Epub ahead of print]

PMID:
31699021
8.

Exploring effects of Souvenaid on cerebral glucose metabolism in Alzheimer's disease.

Scheltens NME, Briels CT, Yaqub M, Barkhof F, Boellaard R, van der Flier WM, Schwarte LA, Teunissen CE, Attali A, Broersen LM, van Berckel BNM, Scheltens P.

Alzheimers Dement (N Y). 2019 Sep 27;5:492-500. doi: 10.1016/j.trci.2019.08.002. eCollection 2019.

9.

Determinants of Cross-Sectional and Longitudinal Health-Related Quality of Life in Memory Clinic Patients Without Dementia.

Banning LCP, Janssen EPCJ, Hamel REG, de Vugt M, Köhler S, Wolfs CAG, Oosterveld SM, Melis RJF, Olde Rikkert MGM, Kessels RPC, Pijnenburg YAL, Koene T, van der Flier WM, Scheltens P, Visser PJ, Verhey FRJ, Aalten P, Ramakers IHGB.

J Geriatr Psychiatry Neurol. 2019 Oct 23:891988719882104. doi: 10.1177/0891988719882104. [Epub ahead of print]

PMID:
31645191
10.

Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies.

van Steenoven I, van der Flier WM, Scheltens P, Teunissen CE, Lemstra AW.

Alzheimers Res Ther. 2019 Oct 10;11(1):83. doi: 10.1186/s13195-019-0537-5.

11.

Applying the ATN scheme in a memory clinic population: The ABIDE project.

Altomare D, de Wilde A, Ossenkoppele R, Pelkmans W, Bouwman F, Groot C, van Maurik I, Zwan M, Yaqub M, Barkhof F, van Berckel BN, Teunissen CE, Frisoni GB, Scheltens P, van der Flier WM.

Neurology. 2019 Oct 22;93(17):e1635-e1646. doi: 10.1212/WNL.0000000000008361. Epub 2019 Oct 9.

PMID:
31597710
12.

Olfactory and gustatory functioning and food preferences of patients with Alzheimer's disease and mild cognitive impairment compared to controls: the NUDAD project.

Doorduijn AS, de van der Schueren MAE, van de Rest O, de Leeuw FA, Fieldhouse JLP, Kester MI, Teunissen CE, Scheltens P, van der Flier WM, Visser M, Boesveldt S.

J Neurol. 2019 Oct 8. doi: 10.1007/s00415-019-09561-0. [Epub ahead of print]

PMID:
31595376
13.

Assessment of the appropriate use criteria for amyloid PET in an unselected memory clinic cohort: The ABIDE project.

de Wilde A, Ossenkoppele R, Pelkmans W, Bouwman F, Groot C, van Maurik I, Zwan M, Yaqub M, Barkhof F, Lammertsma AA, Biessels GJ, Scheltens P, van Berckel BN, van der Flier WM.

Alzheimers Dement. 2019 Nov;15(11):1458-1467. doi: 10.1016/j.jalz.2019.07.003. Epub 2019 Oct 6.

14.

Re-aligning scientific and lay narratives of Alzheimer's disease.

Frisoni GB, Ritchie C, Carrera E, Nilsson P, Ousset PJ, Molinuevo JL, Dubois B, Scheltens P, Minoshima S.

Lancet Neurol. 2019 Oct;18(10):918-919. doi: 10.1016/S1474-4422(19)30323-0. No abstract available.

PMID:
31526751
15.

Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study.

van Maurik IS, Vos SJ, Bos I, Bouwman FH, Teunissen CE, Scheltens P, Barkhof F, Frolich L, Kornhuber J, Wiltfang J, Maier W, Peters O, Rüther E, Nobili F, Frisoni GB, Spiru L, Freund-Levi Y, Wallin AK, Hampel H, Soininen H, Tsolaki M, Verhey F, Kłoszewska I, Mecocci P, Vellas B, Lovestone S, Galluzzi S, Herukka SK, Santana I, Baldeiras I, de Mendonça A, Silva D, Chetelat G, Egret S, Palmqvist S, Hansson O, Visser PJ, Berkhof J, van der Flier WM; Alzheimer's Disease Neuroimaging Initiative.

Lancet Neurol. 2019 Nov;18(11):1034-1044. doi: 10.1016/S1474-4422(19)30283-2. Epub 2019 Sep 13.

PMID:
31526625
16.

Discordant amyloid-β PET and CSF biomarkers and its clinical consequences.

de Wilde A, Reimand J, Teunissen CE, Zwan M, Windhorst AD, Boellaard R, van der Flier WM, Scheltens P, van Berckel BNM, Bouwman F, Ossenkoppele R.

Alzheimers Res Ther. 2019 Sep 12;11(1):78. doi: 10.1186/s13195-019-0532-x.

17.

Cerebral amyloid burden is associated with white matter hyperintensity location in specific posterior white matter regions.

Weaver NA, Doeven T, Barkhof F, Biesbroek JM, Groeneveld ON, Kuijf HJ, Prins ND, Scheltens P, Teunissen CE, van der Flier WM, Biessels GJ; TRACE-VCI study group.

Neurobiol Aging. 2019 Aug 9. pii: S0197-4580(19)30279-9. doi: 10.1016/j.neurobiolaging.2019.08.001. [Epub ahead of print]

18.

Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay.

Shi L, Westwood S, Baird AL, Winchester L, Dobricic V, Kilpert F, Hong S, Franke A, Hye A, Ashton NJ, Morgan AR, Bos I, Vos SJB, Buckley NJ, Kate MT, Scheltens P, Vandenberghe R, Gabel S, Meersmans K, Engelborghs S, De Roeck EE, Sleegers K, Frisoni GB, Blin O, Richardson JC, Bordet R, Molinuevo JL, Rami L, Wallin A, Kettunen P, Tsolaki M, Verhey F, Lleó A, Alcolea D, Popp J, Peyratout G, Martinez-Lage P, Tainta M, Johannsen P, Teunissen CE, Freund-Levi Y, Frölich L, Legido-Quigley C, Barkhof F, Blennow K, Zetterberg H, Baker S, Morgan BP, Streffer J, Visser PJ, Bertram L, Lovestone S, Nevado-Holgado AJ.

Alzheimers Dement. 2019 Nov;15(11):1478-1488. doi: 10.1016/j.jalz.2019.06.4951. Epub 2019 Sep 5.

19.

The "rights" of precision drug development for Alzheimer's disease.

Cummings J, Feldman HH, Scheltens P.

Alzheimers Res Ther. 2019 Aug 31;11(1):76. doi: 10.1186/s13195-019-0529-5. Review.

20.

Use of mild cognitive impairment and prodromal AD/MCI due to AD in clinical care: a European survey.

Bertens D, Vos S, Kehoe P, Wolf H, Nobili F, Mendonça A, van Rossum I, Hort J, Molinuevo JL, Heneka M, Petersen R, Scheltens P, Visser PJ.

Alzheimers Res Ther. 2019 Aug 22;11(1):74. doi: 10.1186/s13195-019-0525-9.

21.

Early restoration of parvalbumin interneuron activity prevents memory loss and network hyperexcitability in a mouse model of Alzheimer's disease.

Hijazi S, Heistek TS, Scheltens P, Neumann U, Shimshek DR, Mansvelder HD, Smit AB, van Kesteren RE.

Mol Psychiatry. 2019 Aug 20. doi: 10.1038/s41380-019-0483-4. [Epub ahead of print]

PMID:
31431685
22.

Physical exercise improves quality of life, depressive symptoms, and cognition across chronic brain disorders: a transdiagnostic systematic review and meta-analysis of randomized controlled trials.

Dauwan M, Begemann MJH, Slot MIE, Lee EHM, Scheltens P, Sommer IEC.

J Neurol. 2019 Aug 14. doi: 10.1007/s00415-019-09493-9. [Epub ahead of print] Review.

PMID:
31414194
23.

Associations of brain pathology, cognitive and physical markers with age in cognitively normal individuals aged 60-102 years.

Legdeur N, Tijms BM, Konijnenberg E, den Braber A, Ten Kate M, Sudre CH, Tomassen J, Badissi M, Yaqub M, Barkhof F, van Berckel BN, Boomsma DI, Scheltens P, Holstege H, Maier AB, Visser PJ.

J Gerontol A Biol Sci Med Sci. 2019 Aug 14. pii: glz180. doi: 10.1093/gerona/glz180. [Epub ahead of print]

PMID:
31411322
24.

Added value of amyloid PET in individualized risk predictions for MCI patients.

van Maurik IS, van der Kall LM, de Wilde A, Bouwman FH, Scheltens P, van Berckel BNM, Berkhof J, van der Flier WM.

Alzheimers Dement (Amst). 2019 Jul 29;11:529-537. doi: 10.1016/j.dadm.2019.04.011. eCollection 2019 Dec.

25.

Clinician-patient communication during the diagnostic workup: The ABIDE project.

Visser LNC, Kunneman M, Murugesu L, van Maurik I, Zwan M, Bouwman FH, Schuur J, Wind HA, Blaauw MSJ, Kragt JJ, Roks G, Boelaarts L, Schipper AC, Schooneboom N, Scheltens P, van der Flier WM, Smets EMA.

Alzheimers Dement (Amst). 2019 Jul 29;11:520-528. doi: 10.1016/j.dadm.2019.06.001. eCollection 2019 Dec.

26.

Cerebrospinal Fluid Amyloid-β Subtypes in Confirmed Frontotemporal Lobar Degeneration Cases: A Pilot Study.

Verwey NA, Teunissen CE, Hoozemans JJM, Rozemuller AJM, Scheltens P, Pijnenburg YAL.

J Alzheimers Dis. 2019;71(1):15-20. doi: 10.3233/JAD-190344.

PMID:
31356209
27.

Retinal thickness as potential biomarker in posterior cortical atrophy and typical Alzheimer's disease.

den Haan J, Csinscik L, Parker T, Paterson RW, Slattery CF, Foulkes A, Bouwman FH, Verbraak FD, Scheltens P, Peto T, Lengyel I, Schott JM, Crutch SJ, Shakespeare TJ, Yong KXX.

Alzheimers Res Ther. 2019 Jul 18;11(1):62. doi: 10.1186/s13195-019-0516-x.

28.

Cognitive and functional progression of dementia in two longitudinal studies.

Wang Y, Haaksma ML, Ramakers IHGB, Verhey FRJ, van de Flier WM, Scheltens P, van Maurik I, Olde Rikkert MGM, Leoutsakos JS, Melis RJF.

Int J Geriatr Psychiatry. 2019 Nov;34(11):1623-1632. doi: 10.1002/gps.5175. Epub 2019 Jul 26.

29.

Development and Usability of ADappt: Web-Based Tool to Support Clinicians, Patients, and Caregivers in the Diagnosis of Mild Cognitive Impairment and Alzheimer Disease.

van Maurik IS, Visser LN, Pel-Littel RE, van Buchem MM, Zwan MD, Kunneman M, Pelkmans W, Bouwman FH, Minkman M, Schoonenboom N, Scheltens P, Smets EM, van der Flier WM.

JMIR Form Res. 2019 Jul 8;3(3):e13417. doi: 10.2196/13417.

30.

Testing Episodic Memory in Elderly Subjects: Not as Simple as It Looks.

Boelaarts L, Meyer SRA, Scheltens P, de Jonghe JFM.

Dement Geriatr Cogn Dis Extra. 2019 Jun 18;9(2):207-216. doi: 10.1159/000499836. eCollection 2019 May-Aug.

31.

Associations between quantitative [18F]flortaucipir tau PET and atrophy across the Alzheimer's disease spectrum.

Timmers T, Ossenkoppele R, Wolters EE, Verfaillie SCJ, Visser D, Golla SSV, Barkhof F, Scheltens P, Boellaard R, van der Flier WM, van Berckel BNM.

Alzheimers Res Ther. 2019 Jul 4;11(1):60. doi: 10.1186/s13195-019-0510-3.

32.

Prognostic value of Alzheimer's biomarkers in mild cognitive impairment: the effect of age at onset.

Altomare D, Ferrari C, Caroli A, Galluzzi S, Prestia A, van der Flier WM, Ossenkoppele R, Van Berckel B, Barkhof F, Teunissen CE, Wall A, Carter SF, Schöll M, Choo ILH, Grimmer T, Redolfi A, Nordberg A, Scheltens P, Drzezga A, Frisoni GB; Alzheimer’s Disease Neuroimaging Initiative.

J Neurol. 2019 Oct;266(10):2535-2545. doi: 10.1007/s00415-019-09441-7. Epub 2019 Jul 2.

PMID:
31267207
33.

Cognitive reserve and clinical progression in Alzheimer disease: A paradoxical relationship.

van Loenhoud AC, van der Flier WM, Wink AM, Dicks E, Groot C, Twisk J, Barkhof F, Scheltens P, Ossenkoppele R; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2019 Jul 23;93(4):e334-e346. doi: 10.1212/WNL.0000000000007821. Epub 2019 Jul 2.

34.

Retinal thickness as a potential biomarker in patients with amyloid-proven early- and late-onset Alzheimer's disease.

Haan JD, van de Kreeke JA, Konijnenberg E, Kate MT, Braber AD, Barkhof F, van Berckel BN, Teunissen CE, Scheltens P, Visser PJ, Verbraak FD, Bouwman FH.

Alzheimers Dement (Amst). 2019 Jun 18;11:463-471. doi: 10.1016/j.dadm.2019.05.002. eCollection 2019 Dec.

35.

Cerebrospinal fluid collection: An informative animation video for patients and caregivers.

Babapour Mofrad R, Visser LNC, Fruijtier AD, Scheltens P, Smets EEMA, van der Flier WM, Teunissen CE.

Alzheimers Dement (Amst). 2019 Jun 12;11:435-438. doi: 10.1016/j.dadm.2019.04.005. eCollection 2019 Dec.

36.

Is retinal vasculature a biomarker in amyloid proven Alzheimer's disease?

Haan JD, van de Kreeke JA, van Berckel BN, Barkhof F, Teunissen CE, Scheltens P, Verbraak FD, Bouwman FH.

Alzheimers Dement (Amst). 2019 May 10;11:383-391. doi: 10.1016/j.dadm.2019.03.006. eCollection 2019 Dec.

37.

White Matter Hyperintensities and Hippocampal Atrophy in Relation to Cognition: The 90+ Study.

Legdeur N, Visser PJ, Woodworth DC, Muller M, Fletcher E, Maillard P, Scheltens P, DeCarli C, Kawas CH, Corrada MM.

J Am Geriatr Soc. 2019 Sep;67(9):1827-1834. doi: 10.1111/jgs.15990. Epub 2019 Jun 6.

PMID:
31169919
38.

Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype.

Vermunt L, Sikkes SAM, van den Hout A, Handels R, Bos I, van der Flier WM, Kern S, Ousset PJ, Maruff P, Skoog I, Verhey FRJ, Freund-Levi Y, Tsolaki M, Wallin ÅK, Olde Rikkert M, Soininen H, Spiru L, Zetterberg H, Blennow K, Scheltens P, Muniz-Terrera G, Visser PJ; Alzheimer Disease Neuroimaging Initiative; AIBL Research Group; ICTUS/DSA study groups.

Alzheimers Dement. 2019 Jul;15(7):888-898. doi: 10.1016/j.jalz.2019.04.001. Epub 2019 Jun 1.

PMID:
31164314
39.

Gray matter T1-w/T2-w ratios are higher in Alzheimer's disease.

Pelkmans W, Dicks E, Barkhof F, Vrenken H, Scheltens P, van der Flier WM, Tijms BM.

Hum Brain Mapp. 2019 Sep;40(13):3900-3909. doi: 10.1002/hbm.24638. Epub 2019 Jun 3.

40.

A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity.

van der Lee SJ, Conway OJ, Jansen I, Carrasquillo MM, Kleineidam L, van den Akker E, Hernández I, van Eijk KR, Stringa N, Chen JA, Zettergren A, Andlauer TFM, Diez-Fairen M, Simon-Sanchez J, Lleó A, Zetterberg H, Nygaard M, Blauwendraat C, Savage JE, Mengel-From J, Moreno-Grau S, Wagner M, Fortea J, Keogh MJ, Blennow K, Skoog I, Friese MA, Pletnikova O, Zulaica M, Lage C, de Rojas I, Riedel-Heller S, Illán-Gala I, Wei W, Jeune B, Orellana A, Then Bergh F, Wang X, Hulsman M, Beker N, Tesi N, Morris CM, Indakoetxea B, Collij LE, Scherer M, Morenas-Rodríguez E, Ironside JW, van Berckel BNM, Alcolea D, Wiendl H, Strickland SL, Pastor P, Rodríguez Rodríguez E; DESGESCO (Dementia Genetics Spanish Consortium), EADB (Alzheimer Disease European DNA biobank); EADB (Alzheimer Disease European DNA biobank); IFGC (International FTD-Genomics Consortium), IPDGC (The International Parkinson Disease Genomics Consortium); IPDGC (The International Parkinson Disease Genomics Consortium); RiMod-FTD (Risk and Modifying factors in Fronto-Temporal Dementia); Netherlands Brain Bank (NBB), Boeve BF, Petersen RC, Ferman TJ, van Gerpen JA, Reinders MJT, Uitti RJ, Tárraga L, Maier W, Dols-Icardo O, Kawalia A, Dalmasso MC, Boada M, Zettl UK, van Schoor NM, Beekman M, Allen M, Masliah E, de Munain AL, Pantelyat A, Wszolek ZK, Ross OA, Dickson DW, Graff-Radford NR, Knopman D, Rademakers R, Lemstra AW, Pijnenburg YAL, Scheltens P, Gasser T, Chinnery PF, Hemmer B, Huisman MA, Troncoso J, Moreno F, Nohr EA, Sørensen TIA, Heutink P, Sánchez-Juan P, Posthuma D; GIFT (Genetic Investigation in Frontotemporal Dementia and Alzheimer’s Disease) Study Group, Clarimón J, Christensen K, Ertekin-Taner N, Scholz SW, Ramirez A, Ruiz A, Slagboom E, van der Flier WM, Holstege H.

Acta Neuropathol. 2019 Aug;138(2):237-250. doi: 10.1007/s00401-019-02026-8. Epub 2019 May 27.

41.

Associations of AD Biomarkers and Cognitive Performance with Nutritional Status: The NUDAD Project.

Doorduijn AS, Visser M, van de Rest O, Kester MI, de Leeuw FA, Boesveldt S, Fieldhouse JLP, van den Heuvel EGHM, Teunissen CE, Scheltens P, van der Flier WM, de van der Schueren MAE.

Nutrients. 2019 May 23;11(5). pii: E1161. doi: 10.3390/nu11051161.

42.

Early recognition and treatment of neuropsychiatric symptoms to improve quality of life in early Alzheimer's disease: protocol of the BEAT-IT study.

Eikelboom WS, Singleton E, van den Berg E, Coesmans M, Mattace Raso F, van Bruchem RL, Goudzwaard JA, de Jong FJ, Koopmanschap M, den Heijer T, Driesen JJM, Vroegindeweij LJHM, Thomeer EC, Hoogers SE, Dijkstra AA, Zuidema SU, Pijnenburg YAL, Scheltens P, van Swieten JC, Ossenkoppele R, Papma JM.

Alzheimers Res Ther. 2019 May 24;11(1):48. doi: 10.1186/s13195-019-0503-2.

43.

Aβ34 is a BACE1-derived degradation intermediate associated with amyloid clearance and Alzheimer's disease progression.

Liebsch F, Kulic L, Teunissen C, Shobo A, Ulku I, Engelschalt V, Hancock MA, van der Flier WM, Kunach P, Rosa-Neto P, Scheltens P, Poirier J, Saftig P, Bateman RJ, Breitner J, Hock C, Multhaup G.

Nat Commun. 2019 May 20;10(1):2240. doi: 10.1038/s41467-019-10152-w.

44.

Assessing cognition and daily function in early dementia using the cognitive-functional composite: findings from the Catch-Cog study cohort.

Jutten RJ, Harrison JE, Lee Meeuw Kjoe PR, Ingala S, Vreeswijk R, van Deelen RAJ, de Jong FJ, Opmeer EM, Aleman A, Ritchie CW, Scheltens P, Sikkes SAM.

Alzheimers Res Ther. 2019 May 15;11(1):45. doi: 10.1186/s13195-019-0500-5.

45.

Dietary Patterns Are Related to Clinical Characteristics in Memory Clinic Patients with Subjective Cognitive Decline: The SCIENCe Project.

Wesselman LMP, Doorduijn AS, de Leeuw FA, Verfaillie SCJ, van Leeuwenstijn-Koopman M, Slot RER, Kester MI, Prins ND, van de Rest O, de van der Schueren MAE, Scheltens P, Sikkes SAM, van der Flier WM.

Nutrients. 2019 May 11;11(5). pii: E1057. doi: 10.3390/nu11051057.

46.

Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort.

Kim M, Snowden S, Suvitaival T, Ali A, Merkler DJ, Ahmad T, Westwood S, Baird A, Proitsi P, Nevado-Holgado A, Hye A, Bos I, Vos S, Vandenberghe R, Teunissen C, Ten Kate M, Scheltens P, Gabel S, Meersmans K, Blin O, Richardson J, De Roeck E, Sleegers K, Bordet R, Rami L, Kettunen P, Tsolaki M, Verhey F, Sala I, Lléo A, Peyratout G, Tainta M, Johannsen P, Freund-Levi Y, Frölich L, Dobricic V, Engelborghs S, Frisoni GB, Molinuevo JL, Wallin A, Popp J, Martinez-Lage P, Bertram L, Barkhof F, Ashton N, Blennow K, Zetterberg H, Streffer J, Visser PJ, Lovestone S, Legido-Quigley C.

Alzheimers Dement. 2019 Jun;15(6):817-827. doi: 10.1016/j.jalz.2019.03.004. Epub 2019 May 8.

47.

High amyloid burden is associated with fewer specific words during spontaneous speech in individuals with subjective cognitive decline.

Verfaillie SCJ, Witteman J, Slot RER, Pruis IJ, Vermaat LEW, Prins ND, Schiller NO, van de Wiel M, Scheltens P, van Berckel BNM, van der Flier WM, Sikkes SAM.

Neuropsychologia. 2019 Aug;131:184-192. doi: 10.1016/j.neuropsychologia.2019.05.006. Epub 2019 May 7.

48.

Alzheimer disease biomarkers may aid in the prognosis of MCI cases initially reverted to normal.

Vermunt L, van Paasen AJL, Teunissen CE, Scheltens P, Visser PJ, Tijms BM; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2019 Jun 4;92(23):e2699-e2705. doi: 10.1212/WNL.0000000000007609. Epub 2019 May 8.

49.

Inflammatory biomarkers in Alzheimer's disease plasma.

Morgan AR, Touchard S, Leckey C, O'Hagan C, Nevado-Holgado AJ; NIMA Consortium, Barkhof F, Bertram L, Blin O, Bos I, Dobricic V, Engelborghs S, Frisoni G, Frölich L, Gabel S, Johannsen P, Kettunen P, Kłoszewska I, Legido-Quigley C, Lleó A, Martinez-Lage P, Mecocci P, Meersmans K, Molinuevo JL, Peyratout G, Popp J, Richardson J, Sala I, Scheltens P, Streffer J, Soininen H, Tainta-Cuezva M, Teunissen C, Tsolaki M, Vandenberghe R, Visser PJ, Vos S, Wahlund LO, Wallin A, Westwood S, Zetterberg H, Lovestone S, Morgan BP; Annex: NIMA–Wellcome Trust Consortium for Neuroimmunology of Mood Disorders and Alzheimer's Disease.

Alzheimers Dement. 2019 Jun;15(6):776-787. doi: 10.1016/j.jalz.2019.03.007. Epub 2019 Apr 30.

50.

Driving Difficulties Among Patients with Alzheimer's Disease and Other Neurodegenerative Disorders.

Fuermaier ABM, Piersma D, de Waard D, Davidse RJ, de Groot J, Doumen MJA, Bredewoud RA, Claesen R, Lemstra AW, Scheltens P, Vermeeren A, Ponds R, Verhey F, De Deyn PP, Brouwer WH, Tucha O.

J Alzheimers Dis. 2019;69(4):1019-1030. doi: 10.3233/JAD-181095.

PMID:
31045516

Supplemental Content

Loading ...
Support Center